Giá StemRIM Inc (SRIMF)

StemRIM, Inc. engages in the research and development of regeneration inducing medicine. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 45 full-time employees. The company went IPO on 2019-08-09. The firm is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.